In the News | Friends of Cancer Research

You are here

In the News

June 3, 2019
The results of a study led by physicians at Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with... Read more
June 3, 2019
Late-breaking studies featured today at this morning’s press briefing as the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting continues included the phase 3 OSLO-COMET trial, the... Read more
June 3, 2019
It may be possible to double the number of patients eligible for clinical trials for advanced non–small-cell lung cancer (NSCLC). A study looking at 10,500 health records of advanced NSCLC patients... Read more
June 3, 2019
Dr R. Donald Harvey presents results at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from a study looking at using ASCO’s CancerLinQ database to look expanding clinical trial... Read more
May 31, 2019
While PD-L1 testing has become commonplace with immuno-oncology treatment, the multitude of available antibodies, cut-offs, and scoring algorithms makes this biomarker anything but uniform and... Read more
May 30, 2019
Christiana Care Health System's Gene Editing Institute is preparing to file an investigational new drug application (IND) with the US Food and Drug Administration for a clinical trial protocol that... Read more
May 25, 2019
ASCO recently announced a new task force aimed at reducing disparities and improving outcomes for patients and survivors of cancer who live in rural communities. The new Rural Cancer Care Task Force... Read more
May 22, 2019
Executive Summary Academic institutions confused about agency standards are overly cautious in requiring early-phase studies be conducted under full GMPs, experts say; CBER Director Marks highlights... Read more
May 21, 2019
Executive Summary While the US FDA works to cut time necessary to approve expanded access applications, sponsors are creating delays by mandating patients and institutions sign contracts to gain... Read more
May 20, 2019
Although study findings have identified tumor mutational burden (TMB) as an important factor in responses to cancer therapy, establishing a definition for expression of this biomarker and harmonizing... Read more

Pages